13 March 2020
ConvaTec Group Plc
("ConvaTec" or "the Company")
The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
On 12 March 2020, Brian May, Non-Executive Director and a PDMR, purchased 25,000 Shares at £1.60363 per share. Brian May's resulting shareholding is 25,000 Shares.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
ConvaTec Group Plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")
Nature of the transaction
Purchase of Shares on 12 March 2020
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
12 March 2020
Place of the transaction
London Stock Exchange, Main Market (XLON)
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
Buchanan: Charles Ryland / Chris Lane / Vicky Haynes +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.